Description:
Direct to consumer laboratory testing is also known as patient-ordered laboratory testing. A variety of tests are now available for direct to consumer testing. The growing market for direct-to-consumer laboratory testing may promote awareness of health issues and genetic diseases, which will allow patients to take a more proactive role in their healthcare. With advances in technology, the completion of the sequencing of the human genome and the pressures of the pandemic, direct to consumer lab testing is becoming increasingly popular. Still, clinical laboratories are an essential part of the health industry. It is estimated that the vast majority of physician’s diagnoses are a result of laboratory tests. In addition to diagnosing patients, clinical lab testing is performed to evaluate disease progression, monitor drug treatment and conditions, determine individual therapy, and several other reasons.
Several trends are continuing to shape the direct-to-consumer laboratory testing market including the growing demand for early disease detection and diagnosis, personalized medicine, importance of disease monitoring, consumer acceptance and expanded technologies. This report, The U.S. Market for Direct-to-Consumer (DTC) Laboratory Testing, 2nd Edition, examines these and other essential market trends.
Report Highlights:
- Market Dynamics:
- Overview of the increasing popularity of direct-to-consumer laboratory testing, also known as patient-ordered laboratory testing.
- Examination of how technological advances, the completion of the human genome sequencing, and the pandemic have accelerated the adoption of DTC lab testing.
- Insights into the essential role clinical laboratories play in diagnosing diseases, evaluating disease progression, monitoring drug treatments, and determining individual therapies.
- Consumer Trends:
- Analysis of the growing demand for early disease detection and diagnosis, personalized medicine, and disease monitoring.
- Discussion on consumer acceptance and the impact of expanded technologies on the DTC lab testing market.
Scope and Methodology:
- Market Segmentation:
- Detailed exploration of demographics, aging population, growing incidence of disease, and the regulatory environment.
- Analysis of consumer-driven healthcare, the emphasis on preventative healthcare, and developments in personalized medicine.
- Coverage of trends in mobile devices, informed consent, payment structures, and sales by distribution channel.
- Comprehensive Coverage:
- Issues and Trends:
- Impact of telehealth on DTC testing.
- Profiles of leading companies such as 23andMe, Any Lab Test Now, Color Genomics, Direct Laboratory Services, EasyDNA, Everlywell, Laboratory Corporation of America, MyMedLab, Ombre Gut Health (formerly Thryve), Quest Diagnostics, and Request A Test.
- Leading Participants: Insights into large diagnostic companies and their involvement in the DTC market.
- Issues and Trends:
Competitive Landscape:
- Company Coverage:
- Analysis of key players in the DTC laboratory testing market, including their strategies and market positions.
- Overview of the competitive environment, highlighting the role of major diagnostic companies and their approaches to the DTC market.
Report Scope: The scope of this report covers direct-to-consumer (DTC) laboratory testing, excluding point-of-care and over-the-counter testing where a laboratory is not required. The geographical focus is the United States, with a base year of 2021 and forecasts for 2022-2026.
For further details and to purchase directly, please contact us.
Sample Report: A sample is available as a PDF upon request.
Table: U.S. DTC Laboratory Testing Market 2021-2026 (in millions $)
| Year | Revenues | Percent Change |
| 2021 | $XX Million | XX% |
| 2022 | $XX Million | XX% |
| 2023 | $XX Million | XX% |
| 2024 | $XX Million | XX% |
| 2025 | $XX Million | XX% |
| 2026 | $XX Million | XX% |
| Compound Annual Growth Rate | ||
| 2021-2023 | XX% | |
| 2023-2026 | XX% | |
| 2021-2026 | XX% | |
Source: Kalorama Information
